Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249757 | 0.80 | CES2 (0.44) | CES2RPS6KA3JAK3IDO1TDO2 | |
| SCHEMBL440959 | 0.78 | CES2 (0.58) | CES2IDO1ADRB1MAPTRAPGEF4 | |
| SCHEMBL5543022 | 0.78 | CES2 (0.42) | CES2RPS6KA3JAK3IDO1TDO2 | |
| SCHEMBL347778 | 0.76 | CES2 (0.41) | CES2RPS6KA3JAK3IDO1TDO2 | |
| SCHEMBL1547520 | 0.76 | CES2 (0.41) | CES2RPS6KA3JAK3IDO1TDO2 | |
| SCHEMBL66819 | 0.76 | CES2 (0.46) | CES2RPS6KA3JAK3IDO1TDO2 | |
| SCHEMBL5779021 | 0.76 | CES2 (0.46) | CES2RPS6KA3JAK3IDO1TDO2 | |
| SCHEMBL5543019 | 0.76 | RPS6KA3 (0.43) | CES2RPS6KA3JAK3IDO1TDO2 | |
| SCHEMBL15741510 | 0.76 | CES2 (0.41) | CES2RPS6KA3JAK3IDO1TDO2 | |
| SCHEMBL5468765 | 0.76 | CES2 (0.41) | CES2RPS6KA3JAK3IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006521344-A | — | — | 2006-09-21 | — | — | JP | claimed |
| US-20060122224-A1 | Quinoline and quinoxaline compounds | BECHLE BRUCE M | 2006-06-08 | — | — | US | claimed |
| WO-2006032987-A1 | INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF ARTERIOSCLEROSIS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | claimed |
| EP-1622872-A1 | 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | claimed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | claimed |
| US-20060122224-A1 | Quinoline and quinoxaline compounds | BECHLE BRUCE M | 2006-06-08 | — | — | US | disclosed |
| WO-2006032987-A1 | INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF ARTERIOSCLEROSIS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1622872-A1 | 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122224-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | CES2 487/4885RPS6KA3 2488/4885JAK3 3476/4885 |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | CES2 487/4885RPS6KA3 2488/4885JAK3 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.